Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate vs Interferon-alfa 2b in CTCL
NCT02323659Phase 4Terminated
- Sponsor
- Polish Lymphoma Research Group
- Start
- Jun 2014
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate and Interferon alfa-2b vaginal effervescent tablet in primary cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Polish Lymphoma Research Group. Primary endpoint: Objective Response Rate at 3 years. Started Jun 2014; status: terminated.
02
Drugs
methotrexateInterferon alfa-2b vaginal effervescent tablet
03
Conditions
primary cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02323659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323659.